Skip to content

Morpho-functional Changes After Oral Supplementation of Antioxidants and Anti-inflammatory Treatment in Age-Related Macular Degeneration.

Evaluation of Macular Function and Related Changes in Visual Perception and Retinal Morphology After 6 Months of Use of Oral Supplementation Called MACUPREV, in Patients With Dry Age-related Macular Degeneration (AMD)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03919019
Acronym
MACUPREV
Enrollment
30
Registered
2019-04-18
Start date
2018-01-18
Completion date
2018-11-20
Last updated
2019-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry AMD

Keywords

oral supplementation, mfERG, OCT

Brief summary

In patients with AMD a deterioration of the antioxidant mechanisms of the retina is observed and therefore an increase in the production of free radicals responsible for tissue damage. The Age-Related Eye Disease Study (AREDS) found that the intake of antioxidants reduces the risk of progression of the disease to an advanced stage (choroidal neovascularization or geographic atrophy ) and reduces the loss of visual acuity. In this study the investigators want to analyze the functional retinal changes (mfERG) of the macular region, in patients with dry age-related macular degeneration, after the use for 6 months of an oral supplementation based on Ganoderma lucidum (Reishi), Calendula Officinalis, Lutepure-Marigold ( 5% Lutein and 1% Zeaxanthin) Blueberry, Rutin, Alpha-lipoic acid, Bromelain, NAC, Vtiamine C, B9, B12, D3, Selenium, Zinc and Copper.

Interventions

OTHERMacuprev Group

oral supplementation (Macuprev) 2 capsules per day for 6 months

OTHERPlacebo Group

oral placebo 2 capsules per day for 6 months

Sponsors

Fondazione G.B. Bietti, IRCCS
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

monocentric, prospective, double blind randomized six months study

Eligibility

Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* age\> 50; * dry AMD not in therapy with oral supplements or antioxidants * visual acuity ≥ 20/40 * ability to provide written informed consent and to follow the procedures of the study;

Exclusion criteria

* spherical refractive error greater than ±6 diopters * cylindrical refractive error greater than ±3 dioptres * opacity of diopter means * any active or past retinal pathology other than AMD * history of ocular surgery (\<6 months) * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Change of Multifocal electroretinogram (mfERG) in patients with dry age-related macular degeneration after 6 months follow upFunctional retinal changes after 6 months follow upTo evaluate functional retinal changes of the macular region by multifocal electroretinogram in patients with dry age-related macular degeneration after the use for 6 months of an oral supplementation in tablets based on Ganoderma lucidum (Reishi), Calendula Officinalis, Lutepure-Marigold ( 5% Lutein and 1% Zeaxanthin) Blueberry, Rutin, Alpha-lipoic acid, Bromelain, NAC, Vtiamine C, B9, B12, D3, Selenium, Zinc and Copper. The researchers analyzed the average response amplitude densities (RAD: nanoV/ degree 2) between the first negative peak, N1 and the first positive peak, P1

Secondary

MeasureTime frameDescription
To evaluate correlation between mfERG changes (functional activity) and morphological retinal changes (CRT: central retinal thickness and VD: vessel density at the superficial and deep capillary plexa) after 6 months follow upMorpho-functional retinal relationships after 6 months follow upThe researchers evaluated the linear relationships between the mfERG (Response Amplitude Density (RAD nanoV/degree2) and OCT/OCTA values (CRT in micron and vessel density in mm3) by Pearson's Test after administration of a oral supplementation (Macuprev)

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026